Cash & Equivalents
Idexx Laboratories Cash & Equivalents increased by 11.4% to $200.53M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.3%, from $163.97M to $200.53M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -14.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $232.13M | $145.20M | $144.45M | $204.62M | $114.36M | $99.18M | $112.55M | $111.37M | $132.84M | $331.70M | $453.93M | $397.43M | $401.59M | $308.64M | $288.27M | $163.97M | $164.59M | $208.17M | $180.07M | $200.53M |
| QoQ Change | — | -37.4% | -0.5% | +41.6% | -44.1% | -13.3% | +13.5% | -1.0% | +19.3% | +149.7% | +36.9% | -12.4% | +1.0% | -23.1% | -6.6% | -43.1% | +0.4% | +26.5% | -13.5% | +11.4% |
| YoY Change | — | — | — | — | -50.7% | -31.7% | -22.1% | -45.6% | +16.2% | +234.5% | +303.3% | +256.9% | +202.3% | -7.0% | -36.5% | -58.7% | -59.0% | -32.6% | -37.5% | +22.3% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Idexx Laboratories's cash & equivalents?
- Idexx Laboratories (IDXX) reported cash & equivalents of $200.53M in Q1 2026.
- How has Idexx Laboratories's cash & equivalents changed year-over-year?
- Idexx Laboratories's cash & equivalents increased by 22.3% year-over-year, from $163.97M to $200.53M.
- What is the long-term trend for Idexx Laboratories's cash & equivalents?
- Over 5 years (2020 to 2025), Idexx Laboratories's cash & equivalents has grown at a -14.1% compound annual growth rate (CAGR), from $383.93M to $180.07M.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.